Microscopic Polyangiitis

Microscopic polyangiitis is a systemic vasculitis affecting smal-l and medium-sized vessels and is characteristically associated with a focal and segmental necrotizing glomerulonephritis. It may present as a pulmonary-renal syndrome with rapidly progressive glomerulonephritis and alveolar hemorrhage, but the pattern of disease will vary according to the organ systems involved. Granulomatous disease of the upper or lower respiratory tract is not a feature, and its presence suggests the diagnosis of Wegener's granulomatosis. The etiology of the condition is unclear, but most patients have antineutrophil cytoplasm antibodies (ANCA) with specificity for either myeloperoxidase (MPO) or proteinase 3 (PR3), and there is increasing evidence that these may be pathogenic. Current treatment includes an induction phase using cyclophosphamide and steroids to attain remission, followed by a maintenance phase in which the levels of immunosuppression are gradually reduced. Azathioprine may be substituted for cyclophosphamide at 3 months. Adjunctive plasma exchange or intravenous methylprednisolone is used in the management of either or both severe renal disease and alveolar hemorrhage, and new evidence suggests that plasma exchange is more effective in recovery of renal function. Overall, 1-year survival in systemic vasculitis is around 85%, and up to 50% of patients relapse, although relapse is less common in those with MPO-ANCA. Newer therapies are being explored in an attempt to increase the efficacy and reduce the toxicity of treatment.

KEYWORDS

Systemic vasculitis - ANCA - microscopic polyangiitis

REFERENCES

• 1 Jennette J C, Falk R J, Andrassy K et al.. Nomenclature of systemic vasculitides: proposal of an international consensus conference.  Arthritis Rheum. 1994;  37 187-192
• 2 Davson J, Ball J, Plat R. The kidney in periarteritis nodosa.  Q J Med. 1948;  67 175-202
• 3 Davies D J, Moran J E, Niall J F, Ryan G B. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology?.  Br Med J (Clin Res Ed). 1982;  285 606
• 4 van der Woude F J, Rasmussen N, Lobatto S et al.. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis.  Lancet. 1985;  1 425-429
• 5 Savage C O, Winearls C G, Evans D J, Rees A J, Lockwood C M. Microscopic polyarteritis: presentation, pathology and prognosis.  Q J Med. 1985;  56 467-483
• 6 Falk R J, Jennette J C. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.  N Engl J Med. 1988;  318 1651-1657
• 7 Goldschmeding R, Dolman K M, van den Ende M E, van der Meer-Gerritsen C H, Sonnenberg A, dem Borne A E. The relation of 29 kD C-ANCA antigen to proteinase 3.  APMIS Suppl. 1990;  19 26-27
• 8 Niles J, McCluskey R, Ahmad M, Arnaout M A. Wegener's granulomatosis autoantigen is a novel serine proteinase.  Blood. 1989;  74 1888-1893
• 9 Tervaert J W, Goldschmeding R, Elema J D et al.. Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum.  1990;  33 1264-1272
• 10 Franssen C, Gans R, Kallenberg C, Hageluken C, Hoorntje S. Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies.  J Intern Med. 1998;  244 209-216
• 11 Falk R J, Nachman P H, Hogan S L, Jennette J C. ANCA glomerulonephritis and vasculitis: a Chapel Hill perspective.  Semin Nephrol. 2000;  20 233-243
• 12 Watts R A, Lane S E, Bentham G, Scott D G. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom.  Arthritis Rheum. 2000;  43 414-419
• 13 Gonzalez-Gay M A, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P, Llorca J. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions.  Arthritis Rheum. 2003;  49 388-393
• 14 Hogan S L, Satterly K K, Dooley M A, Nachman P H, Jennette J C, Falk R J. Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis.  J Am Soc Nephrol. 2001;  12 134-142
• 15 Lane S E, Watts R A, Bentham G, Innes N J, Scott D G. Are environmental factors important in primary systemic vasculitis? A case-control study.  Arthritis Rheum. 2003;  48 814-823
• 16 Dolman K M, Gans R O, Vervaat T J et al.. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy.  Lancet. 1993;  342 651-652
• 17 Kallenberg C G, Rarok A, Stegeman C A, Limburg P C. New insights into the pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis.  Autoimmun Rev. 2002;  1 61-66
• 18 Xiao H, Heeringa P, Hu P et al.. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice.  J Clin Invest. 2002;  110 955-963
• 19 Smyth C L, Smith J, Cook H T, Haskard D O, Pusey C D. Anti-myeloperoxidase associated pauci-immune focal segmental glomerulonephritis in rats.  Cleve Clin J Med. 2002;  69(suppl 2) 156
• 20 Guillevin L, Durand-Gasselin B, Cevallos R et al.. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients.  Arthritis Rheum. 1999;  42 421-430
• 21 Hauer H A, Bajema I M, van Houwelingen H C et al.. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups.  Kidney Int. 2002;  61 80-89
• 22 Booth A D, Almond M K, Burns A et al.. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study.  Am J Kidney Dis. 2003;  41 776-784
• 23 Franssen C F, Gans R O, Arends B et al.. Differences between anti-myeloperoxidase- and anti-proteinase 3-associated renal disease.  Kidney Int. 1995;  47 193-199
• 24 Franssen C F, Stegeman C A, Oost-Kort W W et al.. Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis.  J Am Soc Nephrol. 1998;  9 1915-1923
• 25 Hogan S L, Nachman P H, Wilkman A S, Jennette J C, Falk R J. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis.  J Am Soc Nephrol. 1996;  7 23-32
• 26 Mistry N E, Pusey C D, Gaskin G. Markers of pulmonary haemorrhage in microscopic polyangiitis [abstract].  Sarcoidosis Vasc Diffuse Lung Dis. 1996;  13 268
• 27 Eschun G M, Mink S N, Sharma S. Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplasmic antibody microscopic polyangiitis.  Chest. 2003;  123 297-301
• 28 Homma S, Matsushita H, Nakata K. Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides.  Respirology. 2004;  9 190-196
• 29 Savige J, Gillis D, Benson E et al.. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA).  Am J Clin Pathol. 1999;  111 507-513
• 30 Fauci A S, Haynes B F, Katz P, Wolff S M. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years.  Ann Intern Med. 1983;  98 76-85
• 31 Jayne D, Rasmussen N, Andrassy K et al.. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.  N Engl J Med. 2003;  349 36-44
• 32 Cole E, Cattran D, Magil A et al.. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group.  Am J Kidney Dis. 1992;  20 261-269
• 33 Pusey C D, Rees A J, Evans D J, Peters D K, Lockwood C M. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies.  Kidney Int. 1991;  40 757-763
• 34 Frasca G M, Soverini M L, Falaschini A, Tampieri E, Vangelista A, Stefoni S. Plasma exchange treatment improves prognosis of antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis: a case-control study in 26 patients from a single center.  Ther-Apher Dial. 2003;  7 540-546
• 35 Bolton W K, Sturgill B C. Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis.  Am J Nephrol. 1989;  9 368-375
• 36 Andrassy K, Erb A, Koderisch J, Waldherr R, Ritz E. Wegener's granulomatosis with renal involvement: patient survival and correlations between initial renal function, renal histology, therapy and renal outcome.  Clin Nephrol. 1991;  35 139-147
• 37 Gaskin G, Pusey C D. Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis.  Ther Apher. 2001;  5 176-181
• 38 Gaskin G, Pusey C. Long-term outcome after immunosuppression and plasma exchange for severe vasculitis-associated glomerulonephritis [abstract].  J Am Soc Nephrol. 1999;  10 101A
• 39 Klemmer P J, Chalermskulrat W, Reif M S, Hogan S L, Henke D C, Falk R J. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis.  Am J Kidney Dis. 2003;  42 1149-1153
• 40 de Groot K, Adu D, Savage C O. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review.  Nephrol Dial Transplant. 2001;  16 2018-2027
• 41 Nowack R, Gobel U, Klooker P, Hergesell O, Andrassy K, van der Woude F J. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement.  J Am Soc Nephrol. 1999;  10 1965-1971
• 42 Jayne D R, Chapel H, Adu D et al.. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.  QJM. 2000;  93 433-439
• 43 Richter C, Schnabel A, Csernok E, de Groot K, Reinhold-Keller E, Gross W L. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin.  Clin Exp Immunol. 1995;  101 2-7
• 44 Langford C A, Talar-Williams C, Barron K S, Sneller M C. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse.  Am J Med. 2003;  114 463-469
• 45 de Groot K, Rasmussen N, Cohen Tervaert J W, Jayne D. Randomised trial of cycophosphamide versus methotrexate for induction of remission in “non-renal” ANCA-associated vasculitis [abstract].  J Am Soc Nephrol. 2002;  13 2A
• 46 Schmitt W H, Hagen E C, Neumann I, Nowack R, Flores-Suarez L F, van der Woude F J. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients.  Kidney Int. 2004;  65 1440-1448
• 47 Lockwood C M. Refractory Wegener's granulomatosis: a model for shorter immunotherapy of autoimmune diseases.  J R Coll Physicians Lond. 1998;  32 473-478
• 48 Specks U, Fervenza F C, McDonald T J, Hogan M C. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.  Arthritis Rheum. 2001;  44 2836-2840
• 49 Stone J H. Current status of tumor necrosis factor inhibition strategies in the treatment of vasculitis.  Kidney Blood Press Res. 2003;  26 240-248
• 50 Booth A, Harper L, Hammad T et al.. Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis.  J Am Soc Nephrol. 2004;  15 717-721
• 51 Birck R, Warnatz K, Lorenz H M et al.. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy.  J Am Soc Nephrol. 2003;  14 440-447
• 52 Allen A, Pusey C, Gaskin G. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis.  J Am Soc Nephrol. 1998;  9 1258-1263
• 53 Stegeman C A, Tervaert J W, van Son W J, Tegzess A M. Necrotizing glomerulonephritis associated with antimyeloperoxidase antibodies in a renal transplant recipient with renal failure of unknown origin.  Nephrol Dial Transplant. 1994;  9 839-842
• 54 Elmedhem A, Adu D, Savage C O. Relapse rate and outcome of ANCA-associated small vessel vasculitis after transplantation.  Nephrol Dial Transplant. 2003;  18 1001-1004
• 55 Nachman P H, Segelmark M, Westman K et al.. Recurrent ANCA-associated small vessel vasculitis after transplantation: a pooled analysis.  Kidney Int. 1999;  56 1544-1550
• 56 Gallagher H, Kwan J T, Jayne D R. Pulmonary renal syndrome: a 4-year, single-center experience.  Am J Kidney Dis. 2002;  39 42-47
• 57 Hoffman G S, Kerr G S, Leavitt R Y et al.. Wegener granulomatosis: an analysis of 158 patients.  Ann Intern Med. 1992;  116 488-498
• 58 Stillwell T J, Benson Jr R C, DeRemee R A, McDonald T J, Weiland L H. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis.  Arthritis Rheum. 1988;  31 465-470
• 59 Kamesh L, Harper L, Savage C O. ANCA-positive vasculitis.  J Am Soc Nephrol. 2002;  13 1953-1960
• 60 Bajema I M, Hagen E C, Hermans J et al.. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis.  Kidney Int. 1999;  56 1751-1758
• 61 Hauer H A, Bajema I M, van Houwelingen H C et al.. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients.  Kidney Int. 2002;  62 1732-1742
• 62 Jayne D, Rasmussen N, Andrassy K et al.. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.  N Engl J Med. 2003;  349 36-44
• 63 Nachman P H, Hogan S L, Jennette J C, Falk R J. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis.  J Am Soc Nephrol. 1996;  7 33-39
• 64 Gaskin G, Savage C O, Ryan J J et al.. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis.  Nephrol Dial Transplant. 1991;  6 689-694
• 65 Tervaert J W, Huitema M G, Hene R J et al.. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre.  Lancet. 1990;  336 709-711
• 66 Han W K, Choi H K, Roth R M, McCluskey R T, Niles J L. Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis.  Kidney Int. 2003;  63 1079-1085